<DOC>
	<DOCNO>NCT00715104</DOCNO>
	<brief_summary>This open label , Phase 2 trial immunotherapy sipuleucel-T neoadjuvant treatment men localize prostate cancer .</brief_summary>
	<brief_title>Sipuleucel-T Neoadjuvant Treatment Prostate Cancer</brief_title>
	<detailed_description>This single center , open label , Phase 2 study . Subjects treat 3 infusion sipuleucel-T prior schedule radical prostatectomy ( RP ) surgery . To assess immune response follow treatment sipuleucel-T , tissue prostatectomy specimen compare tissue core biopsy specimen obtain prior treatment sipuleucel T. Following RP , subject randomize receive either booster infusion sipuleucel T treatment sipuleucel-T ( i.e. , booster : booster ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Adenocarcinoma prostate . Subject schedule RP initial therapy localize prostate cancer . Subject ≥ 18 year age . Subject Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Subject adequate hematologic , renal , liver function . Subject evidence metastasis . Subject receive hormone , include luteinizing hormonereleasing hormone agonist , antiandrogens , 5 αreductase inhibitor time prior study screen . Subject receive prior radiation therapy chemotherapy prostate cancer . Subject receive systemic steroid therapy within 14 day . Subject history stage III great cancer , exclude prostate cancer . Subjects history basal squamous cell skin cancer allow , provide subject adequately treat diseasefree time study screen . Subjects history stage I II cancer must adequately treated diseasefree ≥ 3 year prior study screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>